ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript

Key event: LOTIS-5 (Phase III confirmatory of ZYNLONTA + rituximab) is due to read out in Q2 2026, and LOTIS-7 (ZYNLONTA + glofitamab in second-line+ DLBCL) is expected by end-2026. ZYNLONTA is currently approved in third-line-plus DLBCL; management is pursuing earlier-line DLBCL and indolent lymphoma indications to maximize product value and expects sales growth driven by these programs.

Analysis

The story is a classic near-term binary embedded in a longer commercialization runway: clinical readouts and label expansion are catalysts that can re-rate expectations, but true value depends on payer behavior and execution in oncology clinics. A positive confirmatory signal will likely reprice ADCT by compressing perceived clinical risk, but the incremental commercial value will be constrained by how quickly prescribers substitute an ADC for one-time, high-cost modalities and by reimbursement negotiations that typically take 6–18 months post-label expansion.

Second-order supply-chain winners would be CDMOs that can scale complex linker-payload chemistry and sterile fill/finish for cytotoxic conjugates; constrained capacity or specific payload shortages could create a production bottleneck that slows launch sequencing even after regulatory wins. Conversely, established high-cost therapies (e.g., autologous CAR-T and some bispecific franchises) are at risk of elastic demand losses in earlier lines if real-world safety and outpatient administration economics favor ADCs.

Key risks: larger, more heterogeneous patient populations in earlier-line settings can unmask safety signals and dilute response rates, reversing market enthusiasm quickly. Time horizons split: days–weeks for headline-driven volatility around readouts, 3–12 months for initial reimbursement and hospital formulary uptake, and multiple years for therapy-class displacement or durable label capture.

Key Decisions for Investors

• Tactical long with defined downside: Buy ADCT shares or 6–12 month ATM call options sized for a 3–5% portfolio position ahead of near-term readouts; cap downside with a 25–35% stop-loss or by buying protective puts. R/R: expect a 50–150% upside on a clean readout and accelerated uptake; downside is binary (50%+ on negative outcome).
• Defined‑risk option spread: Enter a 9–12 month bullish call spread on ADCT (buy nearer‑term ATM call, sell 30–40% OTM call) to limit premium spend while retaining upside to label expansion. This reduces theta decay vs naked calls and targets 2–3x return on a positive outcome within a year.
• Relative‑value pair: Long ADCT / Short IMGN (ImmunoGen) equal notional for 3–9 months to express ADC commercialization outperformance while hedging broader oncology beta. R/R: captures execution differentiation; loss if sector-wide bid lifts both names equally.
• Event hedge around commercialization risk: If long shares, purchase short‑dated puts around expected reimbursement windows (3–6 months post-readout) to protect against delayed uptake or adverse pricing rulings. Cost is insurance against multi-quarter revenue compression that would materially reset multiples.